33.77 -0.27(-0.79%) Date: Jun 27, 4:34PM EDT

Johnson & Johnson (JNJ): Street Shrugs Off Pfizer Inc.'s (PFE) Remicade Threat

Analysts weigh in on Johnson and Johnson's prospects as cheaper competition to Remicade looms closer

Will Pfizer Inc.'s (PFE) Xeljanz Cure Ulcerative Colitis?

Pfizer has to look for multiple options in order to expand the label expansion of its drugs due to fierce competition

Pfizer Inc. (NYSE:PFE): Here's Why Piper Still Sees 'Substantial Upside

Piper Jaffray's analysts weighed in on Pfizer's medium to long-term outlook based on their meeting with the company's management

Pfizer Inc. (PFE) No Longer A Buy At Jefferies

Jefferies analysts believe most of the drivers for Pfizer have already played out

Pfizer, Inc. (NYSE:PFE): UBS Expects Ibrance To Capture 70% Of CDK4/6 Market

UBS analysts weigh in on Novartis' data release for its breast cancer drug ribociclib